Research Associate V
Resume:
ANN DEVINE
Plymouth Meeting, PA 19462 ********@*******.***
SUMMARY
Associate Scientist with expertise in a number of pharmacology functions ranging from in vitro, cell based, and in vivo responsibilities. Proven flexibility and ability to multitask on a variety of projects, generate new assays and provide critical data and performance as a team player.
PROFESSIONAL EXPERIENCE
CEPHALON, West Chester, PA (contracted by Aerotek 04/20/06 hired by Cephalon 01/20/07). 2006-present
Research Associate IV, Oncology Research 2006
• Director, Dr. Bruce A. Ruggeri; Supervisor: Dr. Susan Jones-Bolin
Contracted to perform in vitro, cell-based, and in vivo assays for the Bendamustine project and to advance lead compounds into drug development.
• Determination of bendamustine concentration in various cell lines using the MTS assay
• Performed clonogenicity cell survival studies using the dose of bendamustine determined from MTS assays
• Prepared a research protocol for in vivo glucose tolerance testing in mice and rats
• Prepared a research protocol to measure insulin levels with a Rat Insulin Elisa
• Developed a lung carcinoma tumor model in Nu/Nu mice for radiation studies
• Developed a breast cancer metastatic mouse model that metastasized to the lymph nodes from a cell isolate that I developed
• Determination of Art104 binding to various cancers by flow cytometry.
• Performed PK studies as needed
• Prepared a research protocol for soft-agar assay to be used in radiation
o Animal dosing on weekends
o Proficient in multiple I.V. dosing in mice
o Small animal irradiation
JOHNSON & JOHNSON PHARMACEUTICAL R&D, Spring House, PA 1990 - 2006
Associate Scientist, Oncology Drug Discovery 2001 - 2006
• Team Leader, Dr. Dana Johnson; Supervisor: Dr. Jan Sechler
Performed in vitro, cell-based, and in vivo assays for the c-Met project to advance lead compound into drug development.
• The primary screen: c-Met in vitro kinase autophosphorylation assay
• The secondary c-Met Cell Elisa assay
• Developed assays for the assessment of in vivo activity:
o S114 Mouse Tumor Xenograph PD assay
o Metastatic model for the orthotopic injection of MDA-MB-435S into Mouse Mammary fat pad
o Development of Ovarian Mouse Tumor Xenograph PD assay
• Compound was advanced to drug development.
• Supported additional team projects for PDGF-R and Tubulin programs:
o Cell Proliferation assays in various cell lines
o Abl kinase assay
o PDGF-R kinase and autophosphorylation assay
o Animal dosing on weekends
o Promoted to Associate Scientist
Research Associate – Oncology 2000 - 2001
Robert Wood Johnson Pharmaceutical Research Institute - Dr. Bob Tuman
Responsible for the Matrigel Mouse Model and development of a Mouse model for Cachexia in collaboration with Centocor.
Research Associate – Oncology 1994 - 2000
Janssen Research Foundation - Dr. Dave End
Responsibilities for the farnesyltransferase project were directed to the advancement of Zarnestra for clinical development and FDA approval.
• Cell Proliferation studies in various cancer cell lines
• Support clinical work for Zarnestra with apoptosis studies using flow cytometry
• Immunoblotting for different ras mutations
• Developed a Mouse model for cachexia in collaboration with Centocor. Zarnestra is in process for FDA approval.
PAGE 2 ANN DEVINE
PROFESSIONAL EXPERIENCE continued
Research Associate - Central Nervous System 1990 - 1994
Robert Wood Johnson Research Institute - Dr. Barry Dubinsky
Responsibilities for the Anxiolytic project were a variety of in vivo assays to determine benzodiazepine binding, behavioral pharmacology and safety of novel compounds.
• The primary metrazol induced seizure screen in mice
• The secondary Conflict test in Rats
• Ethanol induced narcosis in mice
• Lethal dose studies in mice and rats
• Precipitated withdrawal studies in mice
• Clonidine induced madriasis
• Apomorphine induced climbing
• CNS test to obtain a broad spectrum classification of CNS effects of compounds based upon direct observation of drug induced responses in mice
• Promoted to Research Associate
JOHNSON & JOHNSON PHARMACEUTICAL R&D continued
Research Assistant - Immunopharmacology 1990
Robert Wood Johnson Research Institute - Dr. William E. Hageman
Responsibilities to support the immunopharmacology project:
• Radioimmunoassays on Zymosan Mouse Model and human white cell preparations
CENOCOR, Malvern, PA 1988 - 1990
Production Technician - Antibody Production
Elizabeth Somers
Purification and processing of antibodies for medical diagnostic kits and running quality assurance tests for antibody purity.
MEDICAL COLLEGE OF PENNSYLVANIA, Philadelphia, PA 1987 - 1988
Research Assistant - Physiology/Biochemistry
Dr. Michael C. Phillips
Separation and electrophoresis of lipoprotein fractions. Support work for the graduate students with electronmicroscopy and chromatofocusing.
EDUCATION
Bachelor of Science - Biology, Arcadia University, Glenside, PA 1987
ADDENDUM ANN DEVINE
PUBLICATIONS
1. End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001 Jan 1;61(1):131-7.
2. Dubinsky B, Vaidya AH, Rosenthal DI, Hochman C, Crooke JJ, DeLuca S, DeVine A, Cheo-Isaacs CT, Carter AR, Jordan AD, Reitz AB, Shank RP. 5-ethoxymethyl-7- fluoro-3-oxo-1,2,3,5 tetrahydrobenzo[4,5]imidazo[1,2a]pyridine-4-N-(2-fluorophenyl)carboxamide (RWJ-51204), a new nonbenzodiazepine anxiolytic. J Pharmacol Exp Ther. 2002 Nov;303(2):777-90
3. Angibaud P, Bourdrez X, Devine A, End DW, Freyne E, Ligny Y, Muller P, Mannens, G, Pilatte I, Poncelet V, Skrzat S, Smets G, Van Dun J, Van Remoortere P, Venet M, Wouters W. 5-imidazolyl-quinolinones, -quinazolinones and -benzo-azepinones as farnesyltransferase inhibitors. Bioorg Med Chem Lett. 2003 May 5;13(9):1543-7.
4. Tuman RW, Mei, J., Ho, C., Baker, J., Lu, H., Burns, C., Devine, A., Tominovich, R., Garrabrant, T., Ludovici, D., Sechler, J., Strobel, E., Skrzat, S., Voina, S., Emanuel, S., Gruninger, R.H., Middleton, S., Galemmo, R., Johnson, D.L. RWJ-540973 – A novel, dual mechanism PDGF receptor kinase inhibitor and tumor ell anit-proliferative agent
5. with broad oral anti-tumor activity in dude mouse human tumor xenograft models. 2005. Submitted Molecular Cancer Therapeutics
6. Ho, CY, Ludovici, DW, Maharoof, U, Mei, J, Sechler, J, Tuman, RW, Strobel, ED, Andraka, L, Yen, H-K, Leo, G, Li, J, Almond, H, Lu, H, DeVine, A, Tominovich, RM, Baker, J, Emanuel, S, Gruninger, RH, Middleton, S, Johnson, DL and Galemmo, RA. (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: PDGF Receptor tyrosine kinase inhibitors with broad anti-proliferative activity against tumor cells. Submitted J. Med. Chem.
SELECTED ABSTRACTS
R115777, a selective farnesyl protein transferase inhibitor (FTI), induces predominantly apoptotic activity in C32 melanoma tumor xenografts.
Smets, G., Van Eyck, N., Devine, A., Bowden, C., Wouters, W., End, D.W. AACR 1999 section 3446, March 1999
Farnesyl Transferase Inhibitor (FTI): Effect of ras activation.
Todd, A.V., Applegate, T.L., Fuery, C.J., Roberts, N.J., Impey, H.L., Devine, A., Skrzat, S. & End, D.W., AACR 1998 section 2168, March 1998
R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI): biochemical and cellular effects in H-ras and K-ras dominant systems.
End, D., Skrzat, S., Devine, A., Angibaud, P., Venet, M., Sanz, G., Bowden, C., AACR 1998 section 1847, March 1998
Contact this candidate